{"id":"https://openalex.org/W2562019533","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.2524","title":"Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors.","display_name":"Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2562019533","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.2524","mag":"2562019533"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.2524","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.2524","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.2524","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029783882","display_name":"Gregory A. Daniels","orcid":"https://orcid.org/0000-0001-9087-8009","observed_orcids":["https://orcid.org/0000-0001-9087-8009"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. A. Daniels","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060897770","display_name":"William Edgar Carson","orcid":"https://orcid.org/0000-0001-7024-7533","observed_orcids":["https://orcid.org/0000-0001-7024-7533"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. E. Carson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000961519","display_name":"Alain C. Mita","orcid":"https://orcid.org/0009-0009-3260-4793","observed_orcids":["https://orcid.org/0009-0009-3260-4793","https://orcid.org/0000-0002-5387-0160"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. C. Mita","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045110376","display_name":"Kari Lynn Kendra","orcid":"https://orcid.org/0000-0001-5936-6689","observed_orcids":["https://orcid.org/0000-0001-5936-6689"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. L. Kendra","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030901855","display_name":"Mohamad H. Rahimy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. H. Rahimy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042534166","display_name":"D. W. Inman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. W. Inman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110708545","display_name":"James Richard Appleman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. R. Appleman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085872163","display_name":"James L. Freddo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. L. Freddo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021686685","display_name":"Douglas G. McNeel","orcid":"https://orcid.org/0000-0003-1471-6723","observed_orcids":["https://orcid.org/0000-0003-1471-6723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. G. McNeel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"2524","last_page":"2524"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.95169997215271,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.95169997215271,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10371","display_name":"Immune Response and Inflammation","score":0.02290000021457672,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.019099999219179153,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tlr7-agonist","display_name":"TLR7 agonist","score":0.8539999723434448},{"id":"https://openalex.org/keywords/oral-prodrug","display_name":"oral prodrug","score":0.8429999947547913},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9259999990463257},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6299999952316284},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8820000290870667},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9279999732971191},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9359999895095825},{"id":"https://openalex.org/keywords/interferon-stimulated-genes","display_name":"interferon-stimulated genes","score":0.9369999766349792},{"id":"https://openalex.org/keywords/oas1","display_name":"OAS1","score":0.7620000243186951},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.6140000224113464},{"id":"https://openalex.org/keywords/immune-activation","display_name":"immune activation","score":0.7350000143051147},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7440000176429749},{"id":"https://openalex.org/keywords/uveal-melanoma","display_name":"uveal melanoma","score":0.8539999723434448},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4659999907016754},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7689999938011169}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.941283643245697},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.641110360622406},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6324114203453064},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6307662129402161},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5884332656860352},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5685851573944092},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.48802366852760315},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.463853120803833},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.44832462072372437},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.438351035118103},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.43281662464141846},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3922279477119446},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.37396538257598877},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3585912585258484},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.24265608191490173}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.2524","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.2524","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.2524","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3196177629","https://openalex.org/W3014302917","https://openalex.org/W4252135974","https://openalex.org/W7134287651","https://openalex.org/W7162682038","https://openalex.org/W4282965143","https://openalex.org/W2947208968","https://openalex.org/W2112100378","https://openalex.org/W4404053028","https://openalex.org/W2740542282"],"abstract_inverted_index":{"2524":[0],"Background:":[1],"ANA773":[2,53,96,157,302],"is":[3,263,315],"an":[4,272],"oral":[5],"prodrug":[6],"of":[7,31,52,118,132,294,326],"a":[8,22,107,196,222],"small":[9],"molecule,":[10],"TLR7-selective":[11],"agonist":[12,262],"which":[13],"has":[14],"demonstrated":[15,284],"pharmacological":[16],"activity":[17,75],"in":[18,24,29,59,76,86,166,216,285,306,333],"preclinical":[19],"studies.":[20],"In":[21],"study":[23,63],"healthy":[25],"volunteers,":[26],"dose-related":[27],"increases":[28],"markers":[30],"interferon-alpha":[32],"dependent":[33],"responses":[34,331],"(e.g.":[35],"oligoadenylate":[36],"synthetase":[37],"(OAS),":[38],"neopterin,":[39],"and":[40,42,73,135,154,183,208,224,248,268,281,330],"OAS1":[41],"other":[43,100],"Interferon":[44],"Stimulated":[45],"Gene":[46],"mRNAs)":[47],"were":[48,93,121],"observed":[49,332],"after":[50],"administration":[51],"with":[54,78,88,95,198,288,308,335],"little":[55],"or":[56],"no":[57],"increase":[58],"circulating":[60],"IFN-alpha.":[61],"This":[62,219],"aimed":[64],"to":[65,212,258],"determine":[66],"the":[67,161,259,318],"MTD,":[68],"pharmacodynamics":[69],"(PD),":[70],"pharmacokinetics":[71],"(PK),":[72],"anti-tumor":[74],"pts":[77,87,120,142,231,307,334],"advanced":[79,89,309],"cancer.":[80],"Methods:":[81],"Phase":[82],"I":[83],"dose":[84,125,148,210,264],"escalation":[85],"solid":[90,310],"tumors.":[91,311],"Pts":[92],"treated":[94,145],"dosed":[97],"orally":[98],"every":[99],"day":[101,109],"for":[102,227,275,321],"14":[103,108],"days":[104],"followed":[105],"by":[106,138,317],"rest":[110],"period,":[111],"on":[112,299],"continuous":[113],"28-day":[114],"cycles.":[115,229],"A":[116],"minimum":[117],"3":[119,190,203],"enrolled":[122],"at":[123,146,205],"each":[124],"level.":[126],"Endpoints":[127],"included":[128,177],"safety,":[129],"PK,":[130],"biomarkers":[131],"immune":[133],"activation":[134],"tumor":[136],"response":[137],"RECIST.":[139],"Results:":[140],"20":[141],"have":[143],"been":[144],"5":[147],"levels":[149],"(50,":[150],"100,":[151],"200,":[152],"400,":[153],"800mg":[155,206],"QOD).":[156],"was":[158,163,209,283,303],"well":[159,304],"tolerated;":[160],"MTD":[162],"not":[164],"reached":[165],"this":[167],"trial.":[168],"CTC":[169],"grade":[170,202],"1-2":[171],"AEs":[172],"considered":[173],"possibly":[174],"treatment":[175,226],"related":[176],"fatigue,":[178],"nausea,":[179],"diarrhea,":[180],"headaches,":[181],"vomiting":[182],"weight":[184],"loss.":[185],"One":[186,192],"pt":[187,193,197,220],"had":[188,194,232],"gr":[189],"fatigue.":[191],"DLT;":[195],"malignant":[199],"melanoma":[200,245,250],"experienced":[201],"neutropenia":[204],"QOD":[207,214,271],"reduced":[211],"600mg":[213],"starting":[215],"cycle":[217],"2.":[218],"achieved":[221],"PR":[223],"continued":[225],"19":[228],"4":[230],"stable":[233],"disease":[234],"(SD):":[235],"adenocystic":[236],"carcinoma":[237,241],"(13":[238],"cycles),":[239,243],"prostatic":[240],"(6":[242],"uveal":[244,249],"(7":[246],"cycles)":[247],"(11":[251],"cycles).":[252],"PK":[253],"analysis":[254],"indicates":[255],"that":[256],"exposure":[257],"active":[260],"TLR7":[261,290,327],"proportional.":[265],"At":[266],"400":[267],"800":[269],"mg":[270],"increased":[273],"expression":[274],"interferon-responsive":[276],"genes":[277,297],"(OAS1,":[278],"ISG15,":[279],"IFIT1":[280],"IFI27)":[282],"PBMCs.":[286],"Consistent":[287],"ongoing":[289],"activation,":[291],"substantial":[292],"induction":[293],"all":[295],"four":[296],"occurred":[298],"D13.":[300],"Conclusions:":[301],"tolerated":[305],"Continued":[312],"clinical":[313],"development":[314],"supported":[316],"early":[319],"evidence":[320,325],"its":[322],"activity,":[323],"including":[324],"agonist-mediated":[328],"pharmacology":[329],"melanoma.":[336]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-01-06T00:00:00"}